Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Betsy Althaus"'
Publikováno v:
Hematological Oncology. 39
Autor:
V.G. Karur, Adam J. Olszewski, Antonia Kwan, Houston Holmes, B.M. Medeiros, Izidore S. Lossos, Anusha Vallurupalli, Mehdi Hamadani, Julio C. Chavez, Chunze Li, Michael C. Wei, Shen Yin, E. Seymour, Carol O'Hear, Lihua E. Budde, Javier Munoz, Betsy Althaus, Herbert Eradat, Juan Pablo Alderuccio, S. Babu
Publikováno v:
Hematological Oncology. 37:564-566
Autor:
Tae Min Kim, Ulrich Jaeger, Javier Munoz, Raluca Negricea, Carol O'Hear, Adam J. Olszewski, Ronald McCord, Miguel Canales, Richard Greil, Betsy Althaus, Tycel Phillips, Cindy Chen, Enkhtsetseg Purev, Anusha Vallurupalli, Yuying Xie, Dok Hyun Yoon, Jason R. Westin
Publikováno v:
Blood. 136:37-38
Introduction: Despite the curative intent of the R-CHOP regimen in the first-line treatment of diffuse large B-cell lymphoma (DLBCL), 35-40% of patients who received R-CHOP will eventually succumb to their disease (Coiffier, et al. Blood 2010; Sarkoz
Publikováno v:
Journal of Clinical Oncology. 39:TPS7575-TPS7575
TPS7575 Background: Prognosis is poor for patients with R/R DLBCL, particularly those who are ineligible for autologous stem cell transplant (ASCT) or who relapse after second-line therapy (Gisselbrecht C, et al. Br J Haematol 2018). While chimeric a
Autor:
Betsy Althaus, Tina van der Horst, Eric Van Cutsem, Manish A. Shah, Hyun Cheol Chung, Yoon-Koo Kang, Hugo Castro, Jaffer A. Ajani, Marie Laurence Harle-Yge, Atsushi Ohtsu, Peter C. Thuss-Patience, Gail Lewis Phillips, György Bodoky, Wasat Mansoor, Kohei Shitara
Publikováno v:
The Lancet Oncology. 18:640-653
Summary Background Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is no established therapy in the second-line setting. In GATSBY, we examined the efficacy and t
Autor:
Julian Zhou, Hongjian Yang, Hweichung Wang, Da Pang, Yixiang Mao, Seok Yun Kang, Chuan Wang, Yongsheng Wang, Kunwei Shen, Jennifer Eng-Wong, Wei Li, Zefei Jiang, Zhimin Shao, Jae Hong Seo, Junjie Li, Shude Cui, Suphawat Laohawiriyakamol, Ning Liao, Shusen Wang, Yuan Ching Chang, Betsy Althaus
Publikováno v:
Gland Surg
Importance Prospective assessment of treatments known to benefit patients in global clinical trials in specific racial groups is essential. Objective To compare the efficacy, safety, and tolerability of adding pertuzumab to trastuzumab and docetaxel
Autor:
Deepa Lalla, Liang Fang, Sara A. Hurvitz, Joohyuk Sohn, Manfred Welslau, David Miles, Véronique Diéras, Betsy Althaus, Ellie Guardino
Publikováno v:
Cancer. 120:642-651
BACKGROUND This report describes the results of an analysis of patient-reported outcomes from EMILIA (TDM4370g/BO21977), a randomized phase 3 study of the antibody–drug conjugate trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in hu
Autor:
Manfred, Welslau, Veronique, Diéras, Joo-Hyuk, Sohn, Sara A, Hurvitz, Deepa, Lalla, Liang, Fang, Betsy, Althaus, Ellie, Guardino, David, Miles
Publikováno v:
Cancer. 120(5)
This report describes the results of an analysis of patient-reported outcomes from EMILIA (TDM4370g/BO21977), a randomized phase 3 study of the antibody-drug conjugate trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal
Autor:
Peter C. Thuss-Patience, Manish A. Shah, Eric Van Cutsem, Betsy Althaus, Yoon-Koo Kang, Jaffer A. Ajani, Yongzhe Piao, Tina van der Horst, Atsushi Ohtsu, Marie-Laurence Harle-Yge
Publikováno v:
Journal of Clinical Oncology. 34:5-5
5 Background: Trastuzumab (H) + capecitabine/fluorouracil + cisplatin is standard of care for 1st-line HER2-positive MGC/GEJC but there is no established HER2-targeted 2nd-line regimen. T-DM1 (H linked to DM1) is approved for HER2-positive metastatic
Autor:
Jeffrey, Crawford, Betsy, Althaus, James, Armitage, Douglas W, Blayney, Spero, Cataland, David C, Dale, George D, Demetri, James, Foran, Mark L, Heaney, Sally, Htoy, Dwight D, Kloth, Gary H, Lyman, Laura, Michaud, Susannah, Motl, Saroj, Vadhan-Raj, Michael K, Wong
Publikováno v:
Journal of the National Comprehensive Cancer Network : JNCCN. 3(4)